Rx Medicare

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 as a migraine prevention therapy in people who suffer from 3 or more migraine attacks per month. ADX10059 is a first-in-class migraine prophylactic which works by inhibiting the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). Addex believes mGluR5 may be a key player in a neural process that initiates migraine headaches.

Read More…

Related Posts

• Addex Ends Migraine Prevention Study
• MAP Pharmaceuticals Phase 3 Trial Of Levadex? Migraine Product Candidate Meets All Four Primary Endpoints
• MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
• MAP Pharmaceuticals Announces Completion Of Enrollment In Phase 3 Clinical Trial Of MAP0004 In Patients With Migraine
• Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial In Patients With Migraine Headaches
• Telcagepant Proven As A Safe And Effective Migraine Treatment In Phase III Trial
• Pharmacy Swine Flu Trial Moves Into Phase II – Pharmaceutical Society Of Australia
• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• Third Party Reexamination Of Javelin Pharmaceuticals’ Phase III Trial Data For Ereska Yields Statistically Significant Primary Endpoint
• Trigemina Conducting Phase IIa Clinical Trial In Chronic Daily Headache
• Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch
• NuPathe Reports Positive Phase III Results For Zelrix, A Novel Transdermal Patch For Acute Migraine
• Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results In Postoperative Orthopedic Pain
• Targeting Glutamate Receptors For Migraine Prevention
• PAION Initiates Phase II Trial With Its Anesthetic/Sedative CNS 7056

Tags: addex, adx10059, migraine, phase, prevention, starts, trial

This entry was posted on Friday, January 16th, 2009 at 11:01 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.